CIA
SRPT icon

Concurrent Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Concurrent Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,080
Closed -$219K – 2203
2026
Q1 		$219K Buy
+10,080
New +$195K ﹤0.01% 1694

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Concurrent Investment Advisors's SRPT Position: Q2 2026 in Review

Concurrent Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 10,080 shares — an estimated $219K sold.

Concurrent Investment Advisors first reported a position in SRPT in Q1 2026 and held it in 1 quarter. The position peaked at $219K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Concurrent Investment Advisors reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Concurrent Investment Advisors sold 10,080 Sarepta Therapeutics shares in Q2 2026, an estimated $219K.
  • Concurrent Investment Advisors first reported a position in Sarepta Therapeutics in Q1 2026 and held it in 1 quarter.
  • Concurrent Investment Advisors's Sarepta Therapeutics position peaked at $219K in Q1 2026.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.